639468-72-7

Basic information

• Product Name: phenyl(tetrahydro-2H-pyran-4-yl)Methanone
• Synonyms: phenyl(tetrahydro-2H-pyran-4-yl)Methanone;4-benzoyloxane;oxan-4-yl(phenyl)methanone
• CAS NO: 639468-72-7
• Molecular Formula: C₁₂H₁₄O₂
• Molecular Weight: 190.23836
• EINECS: -0
• Mol File: 639468-72-7.mol
• Article Data: 10

Chemical Properties

• Melting Point: 57-58 °C
• Boiling Point: 307.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.090±0.06 g/cm3(Predicted)
• CAS DataBase Reference: phenyl(tetrahydro-2H-pyran-4-yl)Methanone(CAS DataBase Reference)
• NIST Chemistry Reference: phenyl(tetrahydro-2H-pyran-4-yl)Methanone(639468-72-7)
• EPA Substance Registry System: phenyl(tetrahydro-2H-pyran-4-yl)Methanone(639468-72-7)

Safety Data

• Hazardous Substances Data: 639468-72-7(Hazardous Substances Data)

Usage

General Description

Phenyl(tetrahydro-2H-pyran-4-yl)methanone is a chemical compound with the molecular formula C14H16O2. It is a ketone derivative with a phenyl group and a tetrahydro-2H-pyran-4-yl group attached to the carbonyl carbon. phenyl(tetrahydro-2H-pyran-4-yl)Methanone may be used in organic synthesis, medicinal chemistry, and pharmaceutical research. Its specific properties, potential applications, and biological effects are subject to further study and investigation.

Upstream product

• 4295-99-2 tetrahydro-2H-pyran-4-carbonitrile 
• 40191-32-0 tetrahydro-2H-pyran-4-carbonylchloride 
• 2674-04-6 diphenyl cadmium 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 50675-18-8 3,4,5,6-tetrahydro-2H-pyran-4-carbaldehyde 
• 5337-03-1 tetrahydro-2H-pyran-4-carboxylic acid 
• 101765-10-0 tetrahydro-4-(methoxymethylene)-2H-pyran 
• 34270-90-1 2,2'-diiodoethyl ether 
• 98-83-9 isopropenylbenzene 
• 156353-01-4 N-methoxy-N-methyltetrahydro-2H-pyran-4-carboxamide 
• 591-51-5 phenyllithium 
• 110238-91-0 tetrahydropyran-4-carboxylic acid methyl ester 
• 263257-15-4 (tetrahydro-2H-pyran-4-yl)magnesium chloride 
• 98-88-4 benzoyl chloride 

Downstream Products

• 855887-00-2 4-phenyl-5-aza-spiro[2.4]hept-4-ene 
• 216087-92-2 rac-(tetrahydro-2H-pyran-4-yl)(phenyl)methanol 
• 1800345-36-1 (S)-(tetrahydro-2H-pyran-4-yl)(phenyl)methanol 
• 1800345-36-1 (R)-(tetrahydro-2H-pyran-4-yl)(phenyl)methanol 
• 1361052-17-6 C₁₈H₁₃F₅O₂ 
• 1197006-60-2 1-phenyl(tetrahydro-2H-pyran-4-yl)methylamine 
• 1430473-15-6 3-iodo-N-(phenyl(tetrahydro-2H-pyran-4-yl)methyl)-1H-indazole-5-carboxamide 

Relevant articles and documents

TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF

The present applicationpresent application relates to a compound represented by Formula (III) or a pharmaceutically acceptable salt, solvent compound, active metabolite, crystal polymorph, ester, isomer, or prodrug thereof. The application further provides a pharmaceutical composition comprising the compound represented by Formula (III) and a use thereof for preparing a bromodomain inhibitor for preventing or treating various diseases, such as inflammation and cancer, related to the bromodomain.

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS

The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS

The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.